On behalf of the Department of Health and Human Services (HHS), the United States recently sued Gilead Sciences and Gilead Sciences Ireland over their preexposure prophylaxis (PrEP) drugs.
The lawsuit, filed in federal district court in Delaware, alleges that Gilead has infringed on HHS patents stemming from groundbreaking, taxpayer-funded research at the Centers for Disease Control and Prevention (CDC). As a result, the complaint alleges, Gilead has reaped billions of dollars from the sale of Truvada and Descovy, which both contain emtricitabine and tenofovir.
Rubin R. US Sues Gilead, Alleging PrEP Drugs Infringe on HHS Patents. JAMA. 2019;322(24):2374. doi:10.1001/jama.2019.20561
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: